AFG Venture Group Dispatches
Corporate advisory and consultancy in Australia, South East Asia and India.
May 2011: Health and Life Sciences: Outlook 2011 and Beyond
“For the first time in history, lifestyle diseases like diabetes, heart disease, some cancers and others kill more people than communicable ones. Treating these diseases – and futile attempts to ‘cure’ them – costs a fortune, more than one-seventh of our GDP.” – How to Save a Trillion Dollars – Mark Bittman, Columnist, The Opinion [...]
Global Trends in Health
Anushka Patel Senior Director and Chair of the Chronic & Critical Conditions Theme, The George Institute for Global Health What causes most disease and ill-health in China and India? Most people would immediately identify infections such as cholera, typhoid, tuberculosis, malaria and HIV, along with problems relating to maternal and child health. These diseases of [...]
Making A Difference
Ian Dixon Founder and CEO, Genscreen Group Every day I seek to use my own skills – and those around me – to make a tangible difference to the lives of others – and make some money when we are successful. My chosen vocation is the development of human therapeutics (and diagnostics) to solve serious [...]
Cell Therapy Commercialisation
David James Director Life Sciences and Pharmaceutical, Invetech Introduction Cell therapies are being investigated for an ever increasing range of applications to treat infectious diseases such as AIDS, repair spinal cord injuries, repair cartilage, strengthen immune systems, and treat neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and epilepsy. Other potential applications include treating arteriosclerosis [...]
What Is The Future For The Big Pharma Model?
Phil Kearney Director of Licensing & External Research, Merck, Sharp & Dohme The 2010 Pharmaceutical R&D Factbook, compiled by CMR International, painted a gloomy picture of the global pharmaceuticals sector. Most notable was the finding that new drugs launched within the last five years accounted for less than 7 percent of industry sales in 2009, [...]